A novel diagnostic screen for defects in the Fanconi anemia pathway

Blood

Volumn 100, Issue 13, 2002, Pages 4649-4654

  Shimamura, Akiko ^a,b   De Oca, Rocio Montes ^a   Svenson, John L ^a   Haining, Nicholas ^a   Moreau, Lisa A ^a   Nathan, David G ^a   D'Andrea, Alan D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTADIENE DIEPOXIDE; FANCONI ANEMIA GROUP D2 PROTEIN; MITOMYCIN C; PROTEIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW DEPRESSION; CELL ASSAY; CHROMOSOME BREAKAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; FANCONI ANEMIA; GENE TRANSFER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 0037114696     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1399     Document Type: Article

References (57)

1. Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan DG, Orkin SH, eds. Nathan and Oski's Hematology of Infancy and Childhood. Vol 1, 5th ed. Philadelphia, PA: WB Saunders; 1998:237-335.
2. Auerbach A, Buchwald M, Joenje H. In: Scriver CR et al. eds. The Metabolic and Molecular Bases of inherited Disease. New York, NY; MacGraw-Hill; 2001:753-768.
3. D'Andrea AD, Grompe M, Molecular biology of Fanconi anemia: Implications for diagnosis and therapy. Blood. 1997;90:1725-1736.
4. Liu JM. Fanconi's anemia. In: Young NS, ed. Bone Marrow Failure Syndromes. Philadelphia, PA: WB Saunders; 2000:47-68.
5. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-459.
6. Schroeder TM, Tilgen D, Kruger J, Vogel F. Formal genetics of Fanconi's anaemia in the genetics of neoplasia. Nature. 1976;230:370-373.
7. Rosendorff J, Bernstein R, Macdougall L, Jenkins T. Fanconi anemia; another disease of unusually high prevalence in the Afrikaans population of South Africa. Am J Med Genet. 1987;2:793-797.
8. Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol. 1980;45:565-568.
9. Auerbach AD, Adler B, O'Reilly RJ, Kirkpatrick D, Chaganti RS. Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: Relevance to bone marrow transplantation. Cancer Genet Cytogenet. 1983;9:25-36.
10. Yabe M, Yabe H, Matsuda M, et al. Bone marrow transplantation for Fanconi anemia. Adjustment of the dose of cyclophosphamide for preconditioning. Am J Pediatr Hematol Oncol. 1993;15:377-382.
11. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: Application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983;54:431-440.
12. Glanz A, Fraser FC. Spectrum of anomalies in Fanconi anaemia. J Med Genet. 1982;19:412-416.
13. Giampietro PF, Adler-Brecher B, Verlander PC, Pavlakis SG, Davis JG, Auerbach AD. The need for more accurate and timely diagnosis in Fanconi anemia. A report from the International Fanconi Anemia Registry. Pediatrics. 1993;91:1116-1120.
14. Gyger M, Perreault C, Belanger R, Bonny Y, Forest L, Lussier P. Unsuspected Fanconi's anemia and bone marrow transplantation in cases of acute myelomonocytic leukemia. N Engl J Med. 1989;321:120-121.
15. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi anemia registry: Relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-396.
16. Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol. 1993;21:731-733.
17. Auerbach AD, Wolman SR. Carcinogen-induced chromosome breakage in chromosome instability syndromes. Cancer Genet Cytogenet. 1979;1:21-28.
18. Auerbach AD. Fanconi anemia. Dermatol Clin. 1995;13:41-49.
19. Shipley J, Rodeck CH, Garrett C, Galbraith J, Giannelli F. Mitomycin C-induced chromosome damage in fetal blood cultures and prenatal diagnosis of Fanconi's anaemia. Prenat Diagn. 1984;4:217-221.
20. Joenje H, Oostra AB, Wijker M, et al. Evidence for at least eight Fanconi Anemia genes. Am J Hum Genet. 1997;61:940-944.
21. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell. 2001;7:241-248.
22. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anemia gene, FAA. Nat Genet. 1996;14:320-323.
23. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
24. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature. 1992;356:763-767.
25. de Winter JP, Leveille F, van Berkel CGM, et al. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet. 2000;67:1306-1308.
26. de Winter JP, Rooimans MA, van der Weel L, et al. The Fanconi anemia complementation gene FANCF encodes a novel protein with homology to ROM. Nat Genet. 2000;24:15-16.
27. de Winter JP, Waisfisz Q, Rooimans MA, et al. The Fanconi anaemia group G gene is identical with human XRCC9. Nat Genet. 1998;20:281-283.
28. Garcia-Higuera I, Kuang Y, Naf D, Wasik J, D'Andrea AD. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol Cell Biol. 1999;19:4866-4873.
29. de Winter JP, van Der Weel L, de Groot J, et al. The Fanconi anemia protein FANCF forms a., nuclear complex with FANCA, FANCC and FANCG. Human Mol Genet. 2000;9:2665-2674.
30. Medhurst AL, Huber PAJ, Waisfisz Q, de Winter JP, Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Human Mol Genet. 2001;10:423-429.
31. Nakanishi K, Moran A, Hays T, et al. Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. Exp Hematol. 2001;29:842-849.
32. Siddique MA, Nakanishi K, Taniguchi T, Grompe M, D'Andrea AD. Function of the Fanconi anemia pathway in FA complementation group F and D1 cells. Exp Hematol. 2001;29:1448-1455.
33. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7:249-262.
34. Pickart CM. Ubiquitin enters the new millennium. Mol Cell. 2001;8:499-504.
35. Pulsipher M, Kupfer GM, Naf D, et al. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Mol Med. 1998;4:468-479.
36. Naf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD. Functional activity of the Fanconi anemia protein, FAA, requires FAC binding and nuclear localization. Mol Cell Biol. 1998;18:5952-5960.
37. Marcou Y, D'Andrea A, Jeggo PA, Plowman PN. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiother Oncol. 2001;60:75-79.
38. Alter BP. Radio-sensitivity in Fanconi's anemia patients. Radiother Oncol. 2002;62:345-347.
39. Kubbies M, Schindler D, Hoehn H, Schinzel A, Rabinovich PS. Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent endomitoses in Fanconi anemia cells. Am J Hum Genet. 1985;37:1022-1030.
40. Dutrillaux B, Aurias A, Dutrillaux AM, Buriot D, Prieur M. The cell cycle of lymphocytes in Fanconi anemia. Hum Genet. 1982;62:327-332.
41. Seyschab H, Friedl R, Sun Y, et al. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 1995;85:2233-2237.
42. Cassinat B, Guardiola P, Chevret S, et al. Constitutive elevation of serum alpha-fetoprotein in Fan coni anemia. Blood. 2000;96:859-863.
43. Cassinat B, Darsin D, Guardiola P, et al. Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia. Clin Chem. 2001;47:1405-1409.
44. Waldmann TA, McIntire RK. The use of radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974;34:1510-1515.
45. Bloomer JR, Waldmann TA, McIntire KR, Klastkir G. Alpha-fetoprotein in non-neoplastic hepatic disorders. JAMA. 1975;233:38-41.
46. Ferguson-Smith MA, Rawlinson HA, May HM, et al. Avoidance of anencephalic and spina bifida births by maternal serum-alphafetoprotein screening. Lancet. 1978;1:1330-1333.
47. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992;327:588-593.
48. Waldmann TA, McIntyre KR. Serum alpha-fetoprotein levels in patients with ataxia-telangiectasia. Lancet. 1972;282:1112-1115.
49. Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102:98-100.
50. Rojas E, Lopez MC, Valverde M. Single cell gel electrophoresis assay: Methodology and appfications. J Chromatogr B Biomed Sci Appl. 1999;722:225-254.
51. Djuzenova CS, Rothfuss A, Oppitz U, et al. Response to X-irradiation of Fanconi anemia homozygous and heterozygous cells assessed by the single-cell gel electrophoresis (comet) assay. Lab Invest. 2001;81:185-192.
52. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: Molecular basis and clinical significance. Eur J Hum Genet. 1997;5:137-148.
53. Waisfisz Q, Morgan NV, Savino M, et al. Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet. 1999;22:379-383.
54. Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98:2532-2537.
55. Buchwald M. Complementation groups: One or more per gene. Nat Genet. 1995;11:228-230.
56. Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. Blood. 2000;96:4064-4070.
57. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 2002;109:459-472.